Coston McIsaac & Partners’s Takeda Pharmaceutical TAK Stock Holding History

Coston McIsaac & Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4K	Hold	259	–	–	﹤0.01%	710
2025 Q4	$4K	Hold	259	–	–	﹤0.01%	693
2025 Q3	$3K	Hold	259	–	–	﹤0.01%	695
2025 Q2	$4K	Hold	259	–	–	﹤0.01%	639
2025 Q1	$3K	Hold	259	–	–	﹤0.01%	653
2024 Q4	$3K	Hold	259	–	–	﹤0.01%	650
2024 Q3	$3	Hold	259	–	–	﹤0.01%	664
2024 Q2	$3K	Hold	259	–	–	﹤0.01%	638
2024 Q1	$3K	Sell	259 -7	-3%	-$102	﹤0.01%	633
2023 Q4	$3K	Hold	266	–	–	﹤0.01%	630
2023 Q3	$4K	Hold	266	–	–	﹤0.01%	590
2023 Q2	$4K	Hold	266	–	–	﹤0.01%	636
2023 Q1	$4K	Hold	266	–	–	﹤0.01%	625
2022 Q4	$4	Hold	266	–	–	﹤0.01%	626
2022 Q3	$3K	Hold	266	–	–	﹤0.01%	573
2022 Q2	$4K	Buy	+266	New	+$3.8K	﹤0.01%	377

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Coston McIsaac & Partners's TAK Position: Q1 2026 in Review

Coston McIsaac & Partners held its Takeda Pharmaceutical (TAK) position steady in Q1 2026 at 259 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #710.

Coston McIsaac & Partners first reported a position in TAK in Q2 2022 and has held it in 16 quarters since. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Coston McIsaac & Partners held 259 shares of Takeda Pharmaceutical worth $4K as of Q1 2026.
Coston McIsaac & Partners left its Takeda Pharmaceutical share count unchanged in Q1 2026.
Takeda Pharmaceutical made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q1 2026, its #710 holding.
Coston McIsaac & Partners first reported a position in Takeda Pharmaceutical in Q2 2022 and has held it in 16 quarters since.
359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.